Model Informed Drug Development Archives

On-Demand Webinar

Part 3: Oligonucleotide therapeutic development: Clinical pharmacology considerations

In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…

CertaraApril 21, 2021

On-Demand Webinar

Part 2: Oligonucleotide therapeutic development: Pre-clinical and translational considerations

In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…

CertaraApril 21, 2021

On-Demand Webinar

Part 1: What are oligonucleotide therapeutics, and how do they work?

In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…

CertaraApril 21, 2021

On-Demand Webinar

Predicting the Effect of the Dulaglutide-Mediated Gastric Emptying Delay on Drug Exposure

The European Medicines Agency (EMA) recently approved dulaglutide (Trulicity®) at higher doses (3 mg and…

CertaraApril 1, 2021

Publication

Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence

The extent of cross-protection provided by currently licensed bivalent and quadrivalent HPV vaccines versus direct…

CertaraMarch 18, 2021

On-Demand Webinar

Sealing Pharma Commercialization Deals: Creating Optimal Value for Investors

It is crucial for biotech developers to engage in early commercial market assessment to generate…

CertaraMarch 5, 2021

Publication

BPS Article: Model‐Informed Drug Repurposing: a Pharmacometric Approach to Novel Pathogen Preparedness, Response and Retrospection

Abstract During a pandemic caused by a novel pathogen (NP), drug repurposing offers the potential…

CertaraFebruary 9, 2021

White Paper

Leveraging Biosimulation to Inform Optimal Use of COVID-19 Vaccines

CertaraFebruary 3, 2021

On-Demand Webinar

How drug developers can avoid these common mistakes to secure a deal

Emerging biotech companies sometimes lack all of the experience, expertise, or financial capital to successfully…

CertaraJanuary 21, 2021

On-Demand Webinar

Making your biotech program investor-ready

Emerging biotech companies sometimes lack all of the experience, expertise, or financial capital to successfully…

CertaraJanuary 21, 2021

Model Informed Drug Development

Part 3: Oligonucleotide therapeutic development: Clinical pharmacology considerations

Part 2: Oligonucleotide therapeutic development: Pre-clinical and translational considerations

Part 1: What are oligonucleotide therapeutics, and how do they work?

Predicting the Effect of the Dulaglutide-Mediated Gastric Emptying Delay on Drug Exposure

Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence

Sealing Pharma Commercialization Deals: Creating Optimal Value for Investors

BPS Article: Model‐Informed Drug Repurposing: a Pharmacometric Approach to Novel Pathogen Preparedness, Response and Retrospection

Leveraging Biosimulation to Inform Optimal Use of COVID-19 Vaccines

How drug developers can avoid these common mistakes to secure a deal

Making your biotech program investor-ready

Newsletter sign up

Quick links

Solutions

Contact